Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) Shares Sold by U.S. Capital Wealth Advisors LLC

U.S. Capital Wealth Advisors LLC trimmed its position in shares of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) by 29.2% during the fourth quarter, Holdings Channel reports. The institutional investor owned 2,277 shares of the pharmaceutical company’s stock after selling 941 shares during the quarter. U.S. Capital Wealth Advisors LLC’s holdings in Vertex Pharmaceuticals were worth $917,000 as of its most recent SEC filing.

Several other hedge funds also recently added to or reduced their stakes in VRTX. Czech National Bank boosted its position in shares of Vertex Pharmaceuticals by 6.9% during the 3rd quarter. Czech National Bank now owns 52,578 shares of the pharmaceutical company’s stock worth $24,453,000 after purchasing an additional 3,404 shares in the last quarter. Miracle Mile Advisors LLC increased its stake in shares of Vertex Pharmaceuticals by 14.9% during the 3rd quarter. Miracle Mile Advisors LLC now owns 5,816 shares of the pharmaceutical company’s stock valued at $2,705,000 after acquiring an additional 756 shares during the last quarter. Mather Group LLC. increased its stake in shares of Vertex Pharmaceuticals by 2.0% during the 3rd quarter. Mather Group LLC. now owns 4,015 shares of the pharmaceutical company’s stock valued at $1,867,000 after acquiring an additional 80 shares during the last quarter. Kesler Norman & Wride LLC acquired a new position in shares of Vertex Pharmaceuticals during the 3rd quarter valued at about $699,000. Finally, MBM Wealth Consultants LLC grew its holdings in shares of Vertex Pharmaceuticals by 6.7% during the 3rd quarter. MBM Wealth Consultants LLC now owns 2,540 shares of the pharmaceutical company’s stock worth $1,181,000 after purchasing an additional 159 shares during the period. 90.96% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

VRTX has been the subject of a number of analyst reports. Needham & Company LLC restated a “hold” rating on shares of Vertex Pharmaceuticals in a report on Friday, January 31st. Oppenheimer cut Vertex Pharmaceuticals from an “outperform” rating to a “market perform” rating in a research note on Thursday, December 19th. StockNews.com lowered Vertex Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research report on Thursday, November 21st. UBS Group increased their target price on Vertex Pharmaceuticals from $562.00 to $586.00 and gave the stock a “buy” rating in a research report on Tuesday, November 5th. Finally, William Blair reaffirmed an “outperform” rating on shares of Vertex Pharmaceuticals in a research report on Friday, January 31st. One research analyst has rated the stock with a sell rating, nine have assigned a hold rating, seventeen have assigned a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus target price of $502.58.

Vertex Pharmaceuticals Price Performance

NASDAQ:VRTX opened at $482.28 on Wednesday. The company has a quick ratio of 2.20, a current ratio of 2.47 and a debt-to-equity ratio of 0.01. The stock’s 50 day moving average price is $434.73 and its two-hundred day moving average price is $462.62. The firm has a market capitalization of $124.20 billion, a price-to-earnings ratio of -242.35, a P/E/G ratio of 2.39 and a beta of 0.41. Vertex Pharmaceuticals Incorporated has a 12-month low of $377.85 and a 12-month high of $519.88.

Vertex Pharmaceuticals (NASDAQ:VRTX) last posted its earnings results on Monday, November 4th. The pharmaceutical company reported $4.38 EPS for the quarter, beating the consensus estimate of $3.61 by $0.77. The company had revenue of $2.77 billion for the quarter, compared to the consensus estimate of $2.69 billion. Vertex Pharmaceuticals had a negative return on equity of 1.91% and a negative net margin of 4.52%. The firm’s revenue for the quarter was up 11.6% on a year-over-year basis. During the same quarter in the prior year, the business earned $3.67 earnings per share. On average, analysts anticipate that Vertex Pharmaceuticals Incorporated will post -1.93 earnings per share for the current year.

Vertex Pharmaceuticals Profile

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age or older; SYMDEKO/SYMKEVI for people with CF for 6 years of age or older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 year or older who have CF with ivacaftor.